Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
ADVM Adverum Biotechnologies
0.660
-0.018-2.65%
Post Mkt Price
0.6600.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Receivable Turnover(T)
-- -- -- -- -- -- -- 1.3137
Fixed Assets Turnover(T)
-- -- -- -- -- -- -- 0.0903
Total Asset Rate(T)
-- -- -- -- -- -- -- 0.0163
ROIC
-29.41% -39.931% -7.14% -35.988% -18.44% -37.329% 5.84% -32.919%
ROE
-53.57% -56.359% -18.67% -49.558% -29.78% -44.431% -0.55% -38.783%
ROA
-27.38% -37.963% -6.34% -34.278% -17.46% -35.678% 5.28% -31.560%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -- 5.24% -35.491%
ROA 5 Year Average
-- -- -- -- -- -- 8.30% -31.028%
Average 5 Years ROIC
-- -- -- -- -- -- 8.77% -32.591%
Profitability Ratios TTM
Operating Margin
-- -- -- -- -- -- -- -1948.293%
Net Margin
-- -- -- -- -- -- -- -1940.533%
EBITDA Margin
-- -- -- -- -- -- -- -18.8636%
R & D Expense Ratio
-- -- -- -- -- -- -- 1189.080%
Sales Expense Ratio
-- -- -- -- -- -- -- 0.000%
Administration Expense Rate
-- -- -- -- -- -- -- 859.210%
Financial Health Ratios
Long-Term Debt to Equity Ratio
32.79% 45.342% 22.89% 40.633% 471.60% 35.405% 429.42% 31.978%
Total Assets to Common Equity
12.52% 159.531% 10.68% 153.593% 29.40% 143.980% 25.18% 139.073%
Debt to Asset Ratio
43.46% 50.735% 26.46% 43.210% 397.66% 36.238% 360.74% 32.574%
Current Ratio
-45.75% 7.4506 -57.29% 8.035 -41.40% 12.0548 -28.54% 14.8755
Quick Ratio
-47.11% 7.1019 -58.39% 7.7022 -42.48% 11.6648 -29.18% 14.5824
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -- 66.942%
Revenue CAGR(5Y)
-- -- -- -- -- -- -- 38.816%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
CEO: Dr. Laurent Fischer, M.D.
Market: NASDAQ
Listing Date: 07/31/2014
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist